Interview with Matthew Meselson

Questions for Matthew Meselson, Thomas Dudley Cabot professor of the natural sciences at Harvard University, who has been outspoken on the topic of bioterrorism and traveled to Sverdlosk, in the former Soviet Union, to study an anthrax outbreak there in 1979. The Scientist: The Bush Administration's program calls for spending $1.75 billion annually over the next three years to fund bioterrorism research through the National Institute of Allergies and Infectious Diseases (NIAID) alone. That pa

Written byJohn Dudley Miller
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Questions for Matthew Meselson, Thomas Dudley Cabot professor of the natural sciences at Harvard University, who has been outspoken on the topic of bioterrorism and traveled to Sverdlosk, in the former Soviet Union, to study an anthrax outbreak there in 1979.

The Scientist: The Bush Administration's program calls for spending $1.75 billion annually over the next three years to fund bioterrorism research through the National Institute of Allergies and Infectious Diseases (NIAID) alone. That part of the plan directs the institute to discover and produce all necessary vaccines, medicines, and diagnostic tests to defeat bioterrorism, and NIAID Director Anthony Fauci has set a goal of 10 years to complete this work. What's your opinion of this strategy?

Matthew Meselson: There are something like 30 pathogens on the NATO threat list. Why don't we just cure the common cold? [That's similar] in its baldness.

There are some vaccines that we've tried ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies